CYP2C9*3 gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide.

Osvaldo D Castelán-MartínezC Hoyo-VadilloT B Bazán-SotoM CruzE Tesoro-CruzA Valladares-Salgado

Published in: Journal of clinical pharmacy and therapeutics (2018)

The findings suggest that CYP2C9*3 genetic variant independently contributes to good glycaemic control of patients with type 2 diabetes treated with glibenclamide.

Keyphrases

type diabetes
genome wide
copy number
dna methylation
gene expression
genome wide identification